Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Teriparatide (Forteo) vs Vosoritide (Voxzogo)
An educational, source-based comparison of Teriparatide (Forteo) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant PTH(1-34) for severe osteoporosis.
Recombinant fragment of parathyroid hormone (amino acids 1–34). Intermittent dosing stimulates osteoblast activity more than osteoclasts, producing net bone formation and increased bone mineral density.
- Postmenopausal osteoporosis
- Male osteoporosis
- Glucocorticoid-induced osteoporosis
- • FDA-approved.
- • Lifetime use limited to 2 years; transient hypercalcemia possible.
C-type natriuretic peptide analog for achondroplasia.
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.
- Achondroplasia in children ≥5 years (now ≥4 months)
- • FDA-approved.
- • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Teriparatide (Forteo) | Fracture Prevention Trial | NEJM | 2001 | Reduced vertebral fractures by 65% in postmenopausal women. |
| Vosoritide (Voxzogo) | Vosoritide Phase 3 trial | Lancet | 2020 | Increased annualized growth velocity vs placebo in children with achondroplasia. |
Side-effect & safety grid
- FDA-approved.
- Lifetime use limited to 2 years; transient hypercalcemia possible.
- FDA-approved.
- Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Teriparatide (Forteo) vs Vosoritide (Voxzogo) — Key differences
- Class: Teriparatide (Forteo) is classified as Parathyroid Hormone · Anabolic Bone, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
- Primary research focus: Teriparatide (Forteo) — postmenopausal osteoporosis; Vosoritide (Voxzogo) — achondroplasia in children ≥5 years (now ≥4 months).
- Tag: FDA-Approved · Bone vs FDA-Approved · Genetic.